[go: up one dir, main page]

AR019786A1 - Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves - Google Patents

Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves

Info

Publication number
AR019786A1
AR019786A1 ARP990105877A ARP990105877A AR019786A1 AR 019786 A1 AR019786 A1 AR 019786A1 AR P990105877 A ARP990105877 A AR P990105877A AR P990105877 A ARP990105877 A AR P990105877A AR 019786 A1 AR019786 A1 AR 019786A1
Authority
AR
Argentina
Prior art keywords
marek
disease
preparation
birds
virus
Prior art date
Application number
ARP990105877A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR019786A1 publication Critical patent/AR019786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)

Abstract

Líneas celulares de ave que son una base eficaz para el crecimiento e infeccion productiva del virus de la enfermedad de Marek (MDV) a altasconcentraciones. La presente invencion se refiere también a líneas celulares de aves que se han producido poringeniería genética como bases para elcrecimiento e infeccion productiva de virus de la enfermedad de Marek recombinantes a altas concentraciones. Un procedimiento para la preparacion de virus dela enfermedad de Marek en cantidades adecuadas con fines de preparacion de vacunas.
ARP990105877A 1998-12-09 1999-11-18 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves AR019786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11162798P 1998-12-09 1998-12-09

Publications (1)

Publication Number Publication Date
AR019786A1 true AR019786A1 (es) 2002-03-13

Family

ID=22339565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105877A AR019786A1 (es) 1998-12-09 1999-11-18 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves

Country Status (12)

Country Link
US (2) US6410297B1 (es)
EP (1) EP1038952A3 (es)
JP (2) JP3284118B2 (es)
CN (1) CN1191355C (es)
AR (1) AR019786A1 (es)
AU (2) AU767470B2 (es)
BR (1) BR9905779A (es)
CA (1) CA2289951A1 (es)
MX (1) MXPA03009355A (es)
NZ (1) NZ501129A (es)
TW (1) TWI224139B (es)
ZA (1) ZA997114B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
WO2003066093A1 (en) * 2002-02-06 2003-08-14 Lohmann Animal Health Gmbh & Co.Kg A continuous cell line for the production of vaccines
CA2652731A1 (en) * 2008-02-07 2009-08-07 Mark Iv Industries Corp. Real-time location systems and methods
JP6134324B2 (ja) * 2011-10-21 2017-05-24 インターベット インターナショナル ベー． フェー． 感染性喉頭気管炎ウイルスおよびニューカッスル病ウイルス抗原をコードする組換え非病原性マレック病ウイルス構築物
CN103157107A (zh) * 2011-12-14 2013-06-19 普莱柯生物工程股份有限公司 用连续传代细胞系生产鸡马立克氏病疫苗及方法
EP3050572A1 (en) * 2015-01-29 2016-08-03 Ceva Sante Animale Recombinant MDV1 and the uses thereof
US10476549B1 (en) * 2018-05-04 2019-11-12 Futurewei Technologies, Inc. Transmitter linearity built-in-self-test
CN120210132B (zh) * 2025-03-14 2026-02-03 中国兽医药品监察所 一种检测或鉴定mdv-1的杂交瘤细胞株和单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8401120A (nl) * 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5231023A (en) 1990-07-30 1993-07-27 Akzo N.V. Recombinant Marek's disease virus
FR2719056B1 (fr) * 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
JPH11500014A (ja) * 1995-02-21 1999-01-06 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス調製物、ベクター、免疫原、及びワクチン
EP0748867A1 (en) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek's disease vaccine
US5827738A (en) * 1995-10-27 1998-10-27 Board Of Trustees Operating Michigan State University Sustainable chick cell line infected with Marek's disease virus
US6475770B1 (en) * 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines

Also Published As

Publication number Publication date
US6410297B1 (en) 2002-06-25
MXPA03009355A (es) 2004-03-02
CN1256310A (zh) 2000-06-14
EP1038952A2 (en) 2000-09-27
ZA997114B (en) 2001-05-15
JP2000166582A (ja) 2000-06-20
CN1191355C (zh) 2005-03-02
JP3626409B2 (ja) 2005-03-09
US20020132337A1 (en) 2002-09-19
BR9905779A (pt) 2001-02-06
NZ501129A (en) 2001-08-31
AU2004200571A1 (en) 2004-03-11
AU767470B2 (en) 2003-11-13
EP1038952A3 (en) 2001-06-27
JP3284118B2 (ja) 2002-05-20
TWI224139B (en) 2004-11-21
CA2289951A1 (en) 2000-06-09
JP2001206854A (ja) 2001-07-31
HK1027595A1 (en) 2001-01-19
AU5958399A (en) 2000-06-15

Similar Documents

Publication Publication Date Title
ECSP066422A (es) Método para obtener factores citotóxicos provenientes de microorganismos, factores citotóxicos obtenidos y composición farmacéutica y conjunto que los contienen.
EA200200604A1 (ru) Производство вакцин
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
CY1114598T1 (el) Μεθοδος για την ενισχυση ενος ιου φυσαλιδωδους νοσου υπο συνθηκες ελευθερες ορου
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
CY1113138T1 (el) Παραγωγα 10,10-διαλκυλ προστανοϊκου οξεος ως παραγοντες για μειωση ενδο-οφθαλμικης πιεσης
AR019786A1 (es) Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves
CO4700552A1 (es) Lineas de celulas inmortalizadas para el crecimiento de virus
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
KR890000105A (ko) 개의 관상 비루스 왁진
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
Heaney et al. A new genus and species of small ‘tree-mouse’(Rodentia, Muridae) related to the Philippine giant cloud rats
MX2022016176A (es) Linea celular para producir una vacuna contra el virus de la enfermedad de marek y metodos para elaborarla y usarla.
BR0102392A (pt) Extrator para pontas planas rìgidas de um transportador rotativo
FI59812C (fi) Foerfarande foer isolering av en ny rabiesvirusstam
DK1002055T3 (da) Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning
ATE56364T1 (de) Lebender gereinigter impfstoff gegen die marek'sche krankheit.
ES2098866T3 (es) Oligodesoxirribonucleotidos modificados, su preparacion y su utilizacion terapeutica.
Golenishchev et al. New species of vole of “guentheri” group (Rodentia, Arvicolinae, Microtus) from Iran
BR0307512A (pt) Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma
KR20000069501A (ko) 뉴우캐슬병에 대한 난내 백신화
MX9602256A (es) Vacuna contra la enfermedad de marek.
DE69233004D1 (de) Rekombinanter Virus der Marek-Krankheit, Verfahren zur Herstellung dieses Viruses und diesen enthaltender Impfstoff

Legal Events

Date Code Title Description
FB Suspension of granting procedure